Acquired factor V inhibitor in the setting of coronavirus disease 2019 infection

Autor: Joseph Bennett, Marc Hoffmann, Fred V. Plapp, Mark T. Cunningham, Christin Howard

Publikováno v: Blood Coagulation & Fibrinolysis

Factor V inhibitors are a rare cause of life-threatening bleeding. We present a case of an acquired factor V inhibitor likely caused by coronavirus disease 2019 infection. Bleeding was manifested by severe anemia requiring frequent red-cell transfusi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1a6227af292c3b8c899747f9649a44
https://doi.org/10.1097/mbc.0000000000001009

Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B

Autor: Meng-Yao Lu, Daniel Rubens, Manuel Carcao, Masashi Taki, Susan Kearney, Chunduo Shen, Elena Santagostino

Publikováno v: Thrombosis and Haemostasis. 120:737-746

Long-term safety and efficacy data of extended half-life factor IX (FIX) prophylaxis in children with hemophilia B (HB) are sparse. paradigm 5 is a multinational, open-label, single-arm, phase III trial assessing once-weekly (40 IU/kg) prophylactic n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86e689bab225ee32a1b4a852baaa3c67
https://doi.org/10.1055/s-0040-1709521

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial

Autor: Kaan Kavakli, Meriem Belhani, Kirsten Reichwald, Lars Korsholm, Runhui Wu, Hassan M. Yaish, Irina Matytsina, Víctor Jiménez-Yuste, Claire S. Philipp, Tadashi Matsushita

Publikováno v: Haemophilia
Biblos-e Archivo. Repositorio Institucional de la UAM
Universitat Jaume I
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid

Introduction Turoctocog alfa is a recombinant, B domain-truncated factor VIII (FVIII) approved for patients with haemophilia A. Aim To evaluate the safety and efficacy of turoctocog alfa in previously untreated patients (PUPs) with severe haemophilia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbbd9ca996d4fbcd2e1bccf43200c136
http://europepmc.org/articles/PMC7028046

Venous Thrombosis in Acquired Hemophilia: The Complex Management of Competing Pathologies

Autor: Zhen Wan Stephanie Hii, Manu Chhabra, Joseph Rajendran, Kuperan Ponnudurai, Bingwen Eugene Fan

Publikováno v: TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open, Vol 03, Iss 04, Pp e325-e330 (2019)

Introduction Venous thrombosis is rare in the setting of factor VIII (FVIII) deficiency. Cases of deep vein thrombosis (DVT) have been described in hemophiliacs after recent major surgery, or in association with the administration of FVIII concentrat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd75eb30d037b7096fb1f477c61ae0a2
http://europepmc.org/articles/PMC6785302

Development of Acquired Factor V Inhibitor After Surgical Procedure Without the Use of Fibrin Tissue Adhesives: A Case Report

Autor: Hirohisa Hirata, Takeshi Morita, Tetsuya Kasetani, Tomohiro Takeda, Yoshihiko Sakurai

Publikováno v: Cureus

Development of acquired factor V (FV) inhibitor is a rare coagulation disorder. Production of heteroantibodies against bovine FV, a contaminant in fibrin tissue adhesives, is a common cause of this condition in the field of surgery. The development o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a4762cd55cd229b7172469d8359b548
https://doi.org/10.7759/cureus.12708